Pratley R, et al. - Via a randomised, double-blind, double-dummy, phase 3a trial on 950 patients with type 2 diabetes, the researchers intended to compare oral semaglutide (a novel glucagon-like peptide-1 agonist) with subcutaneous liraglutide and placebo. Greater decrease in HbA_1c oral semaglutide than both subcutaneous liraglutide and placebo was noticed. More frequent adverse events with oral semaglutide and subcutaneous liraglutide in comparison with placebo was observed. Hence, the author concluded that in decreasing HbA_1c, oral semaglutide was non-inferior to subcutaneous liraglutide and superior to placebo. Furthermore, it was noticed superior in decreasing bodyweight in contrast to both liraglutide and placebo at week 26. However, safety and tolerability of oral semaglutide and subcutaneous liraglutide were similar.